Top

Published in:

01-03-2019 | Case Report

Giant Hepatic Adenoma in a 12-Year-Old Girl

Authors: Hemant Kumar Singh, Shraddha Patkar, A. M. Polnaya, Mukta Ramadwar, Mahesh Goel

Published in: Journal of Gastrointestinal Cancer | Issue 1/2019

Excerpt

Hepatic adenomas (HA) are benign tumours and constitute 2% of all the liver tumours with an annual incidence of 3–4 per million in Europe and North America [1]. There has been an increase in incidence owing to increase in the use of oestrogen-based contraceptive medication and increased detection due to widespread use of imaging modalities. The common predisposing factor for hepatic adenoma is the use of oestrogen-based oral contraceptive pills. Here, we present a case of giant hepatic adenoma in a young girl in whom no predisposing factors could be identified. …

Rooks JB, Ory HW, Ishak KG, et al. Epidemiology of hepatocellular adenoma-The role of oral contraceptive use. Jr.JAMA. 1979 Aug 17;242(7):644–8 https://doi.org/10.1001/jama.1979.03300070040020

Edmondson HA. Tumours of the liver and intrahepatic bile ducts. section 7, fascicle 25. Atlas of tumour pathology. Washington: Armed Forces Institute of Pathology; 1958.

Baum BJJ, Holtz F, Klein EW. Possible association between benign hepatomas and oral contraceptives. Lancet. 1973;2(7835):926–9. https://doi.org/10.1016/S0140-6736(73)92594-4.CrossRefPubMed

Rosenberg L. The risk of liver neoplasia in relation to combined oral contraceptive use. Contraception. 1991;43(6):643–52. https://doi.org/10.1016/0010-7824(91)90007-3.

Carrasco D, Barrachina M, Prieto M, Berenguer J. Epidemiology of hepatocellular adenoma-The role of oral contraceptive use. N Engl J Med. 1984;310(17):1120–1. https://doi.org/10.1056/NEJM198404263101716.CrossRefPubMed

Coombes GB, Reiser J, Paradinas FJ. An androgen-associated hepatic adenoma in a trans-sexual., Burn I. Br J Surg. 1978;65(12):869–70. https://doi.org/10.1016/0010-7824(91)90007-3.CrossRefPubMed

Fermand JP, Levy Y, Bouscary D, et al. Danazol-induced hepatocellular adenoma. Am J Med. 1990;88(5):529–30. https://doi.org/10.1016/0002-9343(90)90434-F.CrossRefPubMed

Richter WO, Ritter MM, Wiebecke B, et al. Klinefelter's syndrome and liver adenoma. U. J Clin Gastroenterol. 1991;13(2):214–6. https://doi.org/10.1097/00004836-199104000-00020

Alshak NS, Cocjin J, Podesta L, et al. Hepatocellular adenoma in glycogen storage disease type IV. Arch Pathol Lab Med. 1994;118(1):88–91. https://doi.org/10.1136/adc.82.6.479.CrossRefPubMed

10.

Lack EE, Ornvold K. Focal nodular hyperplasia and hepatic adenoma: a review of eight cases in the pediatric age group. J Surg Oncol. 1986;33(2):129–35. https://doi.org/10.1002/jso.2930330217.

11.

Rosencrantz RA, Wu Y, Sonke PY, et al. Giant hepatocellular adenoma in a previously obese thirteen-year-old boy. Ann Hepatol. 2015;14(4):559–63.CrossRef

12.

Flowers BF, McBurney RP, Vera SR. Ruptured hepatic adenoma. A spectrum of presentation and treatment. Am Surg. 1990;56(6):380–3.PubMed

13.

Stoot JHMB, Coelen RJS, de Jong MC, et al. Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases. HPB (Oxford). 2010;12(8):509–22. https://doi.org/10.1111/j.1477-2574.2010.00222.x.CrossRef

14.

Zucman-Rossi J, Jeannot E, Nhieu JT, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology. 2006;43(3):515–24. https://doi.org/10.1002/hep.21068.CrossRefPubMed

15.

Bioulac-Sage P, Laumonier H, Couchy G, et al. Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology. 2009;50(2):481–9. https://doi.org/10.1002/hep.22995.CrossRefPubMed

16.

Erdogan D, van Delden OM, Busch OR, et al. Selective transcatheter arterial embolization for treatment of bleeding complications or reduction of tumor mass of hepatocellular adenomas. Cardiovasc Intervent Radiol. 2007;30(6):1252–8. https://doi.org/10.1007/s00270-007-9108-4.CrossRefPubMed

17.

Karkar AM, et al. Management of hepatocellular adenoma: comparison of resection, embolization and observation. HPB (Oxford). 2013;15(3):235–43. https://doi.org/10.1111/j.1477-2574.2012.00584.x.CrossRef

18.

Deodhar A, Brody LA, Covey AM, et al. Bland embolization in the treatment of hepatic adenomas: preliminary experience. J Vasc Interv Radiol. 2011;22(6):795–799; quiz 800. https://doi.org/10.1016/j.jvir.2011.02.027.CrossRefPubMed

Title: Giant Hepatic Adenoma in a 12-Year-Old Girl
Authors: Hemant Kumar Singh
Shraddha Patkar
A. M. Polnaya
Mukta Ramadwar
Mahesh Goel
Publication date: 01-03-2019
Publisher: Springer US
Published in: Journal of Gastrointestinal Cancer / Issue 1/2019
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-017-9999-5

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Giant Hepatic Adenoma in a 12-Year-Old Girl

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2019

Differential Diagnosis of Pancreatic Epidermoid Cyst Without a Solid Component (Residual Splenic Tissue) vs. Mucinous Cystic Neoplasm

Colon Metastasis, 8 years after Gastrectomy, for Stage I Gastric Cancer

Gallbladder Adenocarcinoma as the First Manifestation of Germline BRCA1 Mutation

Is It Possible a Conservative Approach After Radiochemotherapy in Locally Advanced Rectal Cancer (LARC)? A Systematic Review of the Literature and Meta-analysis

Hepatocellular Carcinoma Surveillance—Experience from Croatian Referral Centre for Chronic Liver Diseases

Music Is Capable of Inducing Changes in Gene Expression in Gastric Cancer Cells

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page